Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2012 Jul 25;131(2):521–531.e12. doi: 10.1016/j.jaci.2012.06.015

Figure 4. Administration of PJ34 reduces lung disease in an established AAD model.

Figure 4

(A–E)AAD was induced in mice and treated with PJ34 as described in online repository Figure E7. (A) Inflammatory cells in the BAL fluid were counted (left graph) and stained for lineage specific markers (middle and right graph). (B) Lung resistance (RL) in response to increasing doses of bronchoconstrictor was measured. (C) Splenocytes were re-stimulated and cytokines were measured. (D) IgE levels were measured in the BAL fluid. (E) Amount of total and OVA specific IgE in the serum of these mice was also determined. The above results are a mean (± SEM) of two independent experiments with 4–5 mice in each group for each experiment. A p value of ≤ 0.05 is indicated by * symbol.